AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer

BACKGROUND: The receptor tyrosine kinase (RTK) epidermal growth factor receptor (EGFR) is overexpressed and an important therapeutic target in Head and Neck cancer (HNC). Cetuximab is currently the only EGFR-targeting agent approved by the FDA for treatment of HNC; however, intrinsic and acquired re...

Descripción completa

Detalles Bibliográficos
Autores principales: Iida, Mari, McDaniel, Nellie K., Kostecki, Kourtney L., Welke, Noah B., Kranjac, Carlene A., Liu, Peng, Longhurst, Colin, Bruce, Justine Y., Hong, Seungpyo, Salgia, Ravi, Wheeler, Deric L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035247/
https://www.ncbi.nlm.nih.gov/pubmed/35461210
http://dx.doi.org/10.1186/s12885-022-09511-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035247/
https://www.ncbi.nlm.nih.gov/pubmed/35461210
http://dx.doi.org/10.1186/s12885-022-09511-6

Ejemplares similares